The 1st ipsilateral dual CG subtype consisted of a single vascular compartment with overlapping territories. Injection of one pedicle resulted in retrograde flow in the 2nd pedicle causing an unacceptable risk of non-target embolization. Attempts at coiling one of the dual ipsilateral pedicles was unsuccessful. Only contralateral unilateral PAE was achieved. The 2nd ipsilateral dual CG subtype consisted of two distinct vascular compartments without territorial overlap. PAE of each pedicle was performed separately. CBCT was necessary for recognition. Bilateral PAE was achieved. Conclusions: Three separate patterns of dual central gland blood supply were identified demonstrating distinct anatomic and hemodynamic features; all having unique implications for PAE.
Purpose: To evaluate patient radiation exposure during prostatic artery embolization (PAE) interventions at a single institution and present a meta-analysis of existing literature. Materials: A query of a prospectively maintained database of patients who underwent PAE for Benign Prostatic Hypertrophy (BPH) without previous surgical intervention from January 2014 to April 2016. Procedural variables such as fluoroscopy time, kerma area product, and reference point air kerma were analyzed. A review of the literature regarding intraprocedural patient radiation exposure in PAE was performed to compare patient exposure data. Results: This study had 23 patients who underwent 24 total procedures. The mean procedural time was 122 Ϯ 5.4 minutes (66-172 mins). The mean fluoroscopy time was 36.7 Ϯ 2.42 minutes (17.1-67.3 mins). The kerma area product was on average 26386 Ϯ 2655 mGy-m 2 (2150-47848 mGy-m 2 ). The reference point air kerma was 1477.04 Ϯ 119.47 mGy (654-2771 mGy). These data were compared with results from 422 total procedures from 6 previously published prospective studies about PAE in BPH, as summarized in Table 1 .
Conclusions: PAE has been previously demonstrated to be a safe procedure and radiation dosages are an important parameter regarding patient safety. Our data suggest that the reference point air kerma reached during PAE is well below the threshold for skin injury, even in patients receiving the highest dose. In addition, 7 patients had Stage 3 or greater chronic kidney disease, and 6 patients had creatinine values greater than 1.5 mg/dL. After obtaining right femoral access, 20 cc of CO 2 was first selectively injected to visualize the hemi-pelvic vasculature either unilaterally or bilaterally, followed by iodinated-contrast angiography to verify the prostatic artery origin prior to embolization. PAE was only attempted following contrast angiography in all cases except one, where PAE was performed after CO 2 angiography only. PAE was then performed by selective embolization of the prostatic artery with Embosphere Microspheres (Merit Medical, South Jordan, Utah). Our primary endpoint was successful prostatic artery origin identification with CO 2 as verified by iodinated contrast in each hemi-pelvis. International prostate symptom score (IPSS) and calculated prostate volumes were recorded before and after PAE to measure PAE success. Results: CO 2 angiography identified the origin of the prostatic artery in 21/28 hemi-pelvises (75% PAE was demonstrated by a 35% mean decrease in prostate volume (n ¼ 9) and a significant improvement in IPSS (n ¼ 6, p ¼ 0.0028) after a mean follow-up of 3.1 months. Conclusions: CO 2 angiography was able to successfully identify the prostatic artery in the majority of patients undergoing PAE. Therefore, CO 2 may be a particularly beneficial contrast medium for PAE when standard agents are contraindicated, and may broaden the patient population for which PAE is a viable treatment option.
